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ttp://dx.doi.org/10.1016/j.ajpath.2013.09.015Because vascular or cardiac mineralization is inversely correlated with morbidity and long-term survival,
we investigated the role of ABCC6 in the calciﬁcation response to cardiac injury in mice. By using two
models of infarction, nonischemic cryoinjury and the pathologically relevant coronary artery ligation,
we conﬁrmed a large propensity to acute cardiac mineralization in Abcc6/ mice. Furthermore, when
the expression of ABCC6 was reduced to approximately 38% of wild-type levels in Abcc6þ/ mice, no
calcium deposits in injured cardiac tissue were observed. In addition, we used a gene therapy approach
to deliver a functional human ABCC6 via hydrodynamic tail vein injection to approximately 13% of
mouse hepatocytes, signiﬁcantly reducing the calciﬁcation response to cardiac cryoinjury. We observed
that the level and distribution of known regulators of mineralization, such as osteopontin and matrix
Gla protein, but not osteocalcin, were concomitant to the level of hepatic expression of human and
mouse ABCC6. We notably found that undercarboxylated matrix Gla protein precisely colocalized within
areas of mineralization, whereas osteopontin was more diffusely distributed in the area of injury,
suggesting a prominent association for matrix Gla protein and osteopontin in ABCC6-related dystrophic
cardiac calciﬁcation. This study showed that the expression of ABCC6 in liver is an important deter-
minant of calciﬁcation in cardiac tissues in response to injuries and is associated with changes in the
expression patterns of regulators of mineralization. (Am J Pathol 2014, 184: 159e170; http://
dx.doi.org/10.1016/j.ajpath.2013.09.015)In the absence of any systemic mineral imbalance, the
calciﬁcation of soft tissues is deﬁned as ectopic or dystrophic
calciﬁcation. Dystrophic mineralization speciﬁcally occurs in
injured, damaged, and/or necrotic tissues. The dystrophic
calciﬁcation of cardiovascular tissues presents a signiﬁcantity Foundation grant 11ADVC-
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.medical concern because it is associated with common
pathological conditions, such as hypercholesterolemia, dia-
betes, and chronic renal failure, as well as certain infrequent
genetic conditions.1,2 Myocardial dystrophic calciﬁcation,
although less frequent than vascular calciﬁcation, may occurAlgemene Nederlandse Vereniging ter Voorkoming van Blindheid and
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Brampton et alin long-term survivors after substantial myocardial in-
farctions as a dramatic manifestation of ectopic calcium
deposition.3e5
In recent years, we and others have demonstrated the role
of ABCC6 mutations in several inheritable pathological
conditions, such as pseudoxanthoma elasticum (PXE;
Mendelian Inheritance of Man 264800),6e9 and in a subset
of patients with generalized arterial calciﬁcation of infancy
(GACI), a disorder otherwise associated with ENPP1 mu-
tations.10,11 ABCC6 is also associated with acquired forms
of pathological calciﬁcation that occur in some patients with
b-thalassemia.12,13 PXE is an autosomal recessive disease14
characterized by progressive (chronic) dystrophic calciﬁca-
tion primarily affecting elastic ﬁbers in dermal, ocular, and
vascular tissues. ABCC6 is an efﬂux pump and a member of
the superfamily of ATP-binding cassette (ABC) genes.15,16
The encoded transmembrane protein is primarily synthe-
sized in the liver and kidneys and localizes to the plasma
membrane.17e19 Two independent lines of Abcc6 knockout
mice replicate the human PXE phenotype.20,21 More
recently, ABCC6 deﬁciency was linked to an acute cardiac
calciﬁcation phenotype referred to as dystrophic cardiac
calciﬁcation (DCC) in several inbred strains of mice,
including C3H/HeJ and DBA/2J.22e27 DCC is an autosomal
recessive trait that was described several decades ago24,26 in
mice and has yet to be described in humans. It corresponds
to a spontaneous condition affecting cardiovascular tissues
that can also be triggered into an acute phenotype by a
speciﬁc dietary regimen or direct injury.28,29 The Dyscalc1
locus affecting DCC was mapped to chromosome 7 by one
of the authors (Z.A.); a single Abcc6 gene mutation leads to
a constitutive decrease in protein levels in the liver.22
Additional loci affecting the penetrance and expression of
the DCC phenotype were mapped to chromosomes 4, 12,
and 14.29
Although the physiological function of ABCC6 toward
calciﬁcation is likely exerted via the systemic circulation of
its substrate(s), the exact mechanism by which this protein
affects the susceptibility to mineralization in distal tissues
has yet to be deﬁned.30,31 However, one must distinguish
the central differences between the DCC phenotype in mice
and the mineralization phenotype of PXE in humans and
mice. PXE is characterized by long-term chronic and pas-
sive development of extracellular matrix calciﬁcation
affecting notably elastic ﬁbers. The induced DCC is acute,
develops over a short period of time, and affects only
muscular tissues.31 Furthermore, the DCC calciﬁcation oc-
curs intracellularly, seemingly initiated within mitochon-
dria.32 Therefore, the chronic and acute molecular pathways
leading to calciﬁcation probably share a mechanism of
initiation (ABCC6 deﬁciency), but their progressions are
most likely distinct.31 Since the original identiﬁcation of
ABCC6 as the causative gene for PXE,6,8 the nature of its
substrate(s) has thus far been elusive and the characteriza-
tion of an ABC transporter endogenous substrate(s) is not an
easy task. Our present knowledge is limited to experimental160data showing the ability of ABCC6 to use ATP to extrude
conjugated metabolites in vitro16,33,34 and the sporadic and
disappointing testing of two potential candidate mole-
cules.30,31,35 To palliate this obstacle, the investigation of
the downstream effects of variable ABCC6 levels on
calciﬁcation and associated regulators is useful to garner
meaningful clues relating to the physiological function of
ABCC6.
To this end, we used two complementary models of
injury to induce heart mineralization, the cardiac cryoinjury
previously developed by one of the authors (Z.A.), which
elicits a quick calciﬁcation response, and the left coronary
artery ligation, representative of ischemic heart injuries.
Furthermore, we focused on the mineralization inhibitor,
matrix Gla protein (MGP), and its undercarboxylated form
(ucMGP), because these are associated with chronic sites of
calciﬁcation in PXE36,37; we also focused on osteopontin
(OPN) and the osteogenic protein, osteocalcin (OC), for
their known role in vascular calciﬁcation and ABCC6-
related mineralization.23,28,38e41
Materials and Methods
Animals
C57BL/6J mice, designated herein as wild-type (WT) con-
trols, were derived from mice purchased from Jackson Lab-
oratories (Bar Harbor, Maine). Abcc6/mice were obtained
from the laboratory of one of the authors (A.A.B.B.) at the
Netherlands Institute for Neuroscience (Amsterdam)20 via a
materials transfer agreement. Abcc6/ mice were generated
on a 129/Ola background and backcrossed >10 times into a
C57BL/6J background. Age-matchedAbcc6/ andAbcc6þ/
littermates used in this study were all derived from the original
breeding pairs from one of the authors (A.A.B.B.) and were
kept separate from the WT line of control mice. All animals
were housed and cared for in an approved animal care facility
in the bioscience building of the University of Hawaii School
ofMedicine (Honolulu, HI). Themice were kept under routine
laboratory conditions with a 12-hour light-dark cycle with
access ad libitum towater and standard chow. The Institutional
Animal Care and Use Committee of the University of Hawaii
approved this study. Experiments have been conducted ac-
cording to national guidelines.
Liver-Speciﬁc Expression of ABCC6 cDNA in Mice
Inducing the transient expression of a speciﬁc cDNA by
hydrodynamic tail vein injection (HTVI) has been described
previously.34,42,43 Brieﬂy, a cDNA encoding human
ABCC6 or b-galactosidase was subcloned into the pLIVE
vector carrying the mouse albumin promoter and a feto-
protein enhancer that ensured a liver-speciﬁc expression
(Mirus Bio, Madison, WI). Plasmid DNA constructs were
delivered to 3-month-old Abcc6/ mice by HTVI. The
injections were performed with a 27-gauge needle with aajp.amjpathol.org - The American Journal of Pathology
ABCC6 Modulates Mineralization after MIvolume of 1 to 2 mL of a DNA-containing TransIT EE
solution, according to the manufacturer’s instruction (Mirus
Bio). Mice were injected with 40 to 60 mg of plasmid. At
least three mice were injected with ABCC6 or empty pLIVE
vector equivalent and subjected to cryoinjury. Mice were
euthanized by standard CO2 procedures 7 days after HTVI.
Myocardial Cryoinjury
At 72 hours after tail vein injection, cardiac injury was
instilled through trans-diaphragm cryoinjury, as previously
described by one of the authors (Z.A.).28,29 Mice were
sacriﬁced by CO2 asphyxiation 7 days after injury to ensure
that the cardiac calciﬁcation phenotype was fully developed.
Hearts were quickly removed, rinsed in PBS, imaged, and
either frozen or appropriately embedded for later immuno-
logical/histological analyses.
Myocardial Ischemia through Ligation of the Left
Coronary Artery
Mouse models of ischemic myocardial infarction have been
described extensively in the literature.44 We used permanent
occlusion of the left anterior descending coronary artery. In
brief, mice were anesthetized with 240 mg/kg of tri-
bromoethanol (Avertin; Sigma, St. Louis, MO) by i.p. in-
jection, endotracheally intubated, and ventilated on a mouse
ventilator (687 series; Harvard Apparatus, Holliston, MA).
Subsequently, an oblique 8-mm incision was made 2 mm
away from the left sternal border toward the left armpit and
the muscles were separated. Next, the chest cavity was
opened and a chest retractor was inserted and opened to
spread the wound 8 to 10 mm in width. The pericardium was
picked up with forceps, pulled apart, and placed behind the
arms of the retractor. The left coronary artery was ligated 1 to
2 mm below the tip of the left auricle in its normal position,
which is expected to induce approximately 40% to 50%
ischemia of the left ventricle. A 7-0 silk ligature was passed
underneath the left coronary artery and tied. Occlusion was
conﬁrmed by observing discoloration of the anterior wall of
the left ventricle, followed by modulation of the electrocar-
diogram (data not shown). The chest cavity was closed, with
pressure applied to the chest wall to reduce the volume of free
air. The muscles and skin were closed layer by layer with 6-
0 absorbable and nylon sutures, respectively. Mice were
sacriﬁced by CO2 asphyxiation 28 days after surgery, and
hearts were quickly removed, rinsed in PBS, imaged, and
processed for immunological/histological analyses.
Immunohistochemistry and Histological Analysis
For immunoﬂuorescent and histochemical staining, hearts
were quickly harvested after euthanasia, placed in optimal
cutting temperature (OCT) compound, and stored at 80C.
Direct histological visualization of calcium deposition after
Alizarin Red S staining on frozen sections was performedThe American Journal of Pathology - ajp.amjpathol.orgon the site of cardiac injury. Brieﬂy, frozen slides (5 mm
thick) were thawed, ﬁxed in 100% acetone for 15 minutes,
and incubated in Alizarin Red S solution (Sigma, St. Louis,
MO) for 5 minutes. Selected sections from each treatment
group were examined for calcium deposition, and images
were collected using an Axioscope 2 ﬂuorescent microscope
(Zeiss, Thornwood, NY).
Immunoﬂuorescent staining of cardiac injury and ABCC6
expression in the liver was performed using frozen OCT
sections (5 mm thick). On heart sections, a mouse mono-
clonal anti-ucMGP antibody (VitaK BV, Maastricht, The
Netherlands) was used to speciﬁcally detect the uncar-
boxylated MGP. OC and OPN were visualized with rabbit
polyclonal antibodies (Millipore, Temecula, CA). ABCC6
expression was detected on liver sections using antibodies
against human ABCC6 (clone M6II-31) and mouse ABCC6
(S-20) (Santa Cruz Biotechnology, Santa Cruz, CA). The
secondary antibody used was Alexaﬂuor 488 (Invitrogen,
Carlsbad, CA). Stained sections were mounted in mounting
medium containing DAPI (Vector Laboratories, Burlin-
game, CA). The distribution of OC, OPN, and MGP in the
heart and human and mouse ABCC6 in the liver was
determined by imaging using an Axioscope 2 ﬂuorescent
microscope. Individual images were collected and processed
with Photoshop CS3 (Adobe, San Jose, CA).
Quantiﬁcation of Regulators of Calciﬁcation
OC, OPN, and total MGP levels were quantiﬁed using
whole tissue protein extract and commercially available
enzyme-linked immunosorbent assay (ELISA; BIOTANG
Inc., Waltham, MA; R&D Systems, Minneapolis, MN; and
EIab, Wuhan, China, respectively). For both the ischemic
and cryoinjured mice, the heart was ﬁrst weighed, the atria
were excised, and only the ventricular region containing the
injured area was retained. Proteins were then extracted from
the ventricular region using the same protocol as for
Western blot analysis and adjusted to 1 mg/mL total protein
before analysis.
Colorimetric Calcium Measurement
The level of mineralization in the hearts was quantiﬁed with
a colorimetric assay45 that measures directly the amount of
calcium within excised tissue, which is then normalized to
the weight of the excised tissues, as previously described.30
Brieﬂy, for cryoinjured hearts, wet tissues corresponding to
the ventral area comprising the injured side of the heart were
separated from the uninjured dorsal region. Both sections
were minced and incubated at room temperature for 48
hours in 0.15N HCl. For ischemic injuries, the same wet
tissue procedure was applied but to the whole ventricular
area of the hearts minus the atria. Samples were centrifuged
at 16,100  g, and the total calcium content of the HCl
supernatant was assessed using the Calcium Liquicolor kit
(Stanbio, Boerne, TX). Calcium content was normalized to161
Figure 1 Surface lesions and calciﬁcation of Abcc6/ and control
mice. Cardiac lesions were obtained through a single transdiaphragm cry-
oinjury. Mice were sacriﬁced 7 days after surgery, and hearts were exposed
by opening the chest cavity and quickly imaged before excision. A: A
representative image obtained with an Abcc6/ mouse illustrates the
macroscopic appearances of the surface lesions outlined with a dashed
circle. The calciﬁcation is visible as white deposits. B and C: The lesions of
a heterozygous Abcc6þ/ mouse and a shameoperated on Abcc6/ mouse
devoid of any obvious white deposits indicating the lack of calciﬁcation. D:
The discoloration of the myocardial tissue after ischemic injury (4 weeks,
permanent occlusion) is delineated by the dashed circle. The arrowhead
points to the suture ligating the left coronary artery.
Brampton et altotal tissue weight before mincing. The calcium values ob-
tained were expressed in mg/dL and per milligram of tissue,
and the ratio of calcium content in injured/uninjured
(background level) tissue was calculated.
Quantitative RT-PCR
We used real-time PCR to determine the level of mRNA
expression for the mouse Abcc6. Total RNA was extracted
from approximately 20 mg of liver sample using the RNeasy
kit (Qiagen Inc., Valencia, VA). The RNAwas converted into
ﬁrst-strand cDNA using a ﬁrst-strand synthesis kit with
random hexamers (GE Healthcare, Buckinghamshire, UK).
The levels of expression of the mouse Abcc6 and human
ABCC6 and corresponding endogenous GAPDH were
detected by quantitative RT-PCR using commercially avail-
able TaqMan probes (Applied Biosystems, Foster City, CA).
Apoptosis Cell Death Detection
Cell death through apoptosis was detected using an in situ
cell death detection kit (Roche Applied Science, Penzberg,
Germany). The protocol was followed according to the
manufacturer’s instructions, with the ﬁnal step being the
detection of apoptosis by ﬂuorescence. For comparison,
parafﬁn-embedded sections from Abcc6/ and WT mice
were taken from the injured area of cryoinjured heart at 1, 3,
and 7 days after treatment. After treatment with the detec-
tion kit, slides were mounted in DAPI-containing mounting
medium (Vector Laboratories), covered with a coverslip,
and viewed on an Axioscope 2 ﬂuorescent microscope, as
previously described.
Western Blot Analysis
Proteins were extracted by homogenizing several whole
lobes of frozen liver tissue on ice in 10 mL of radio-
immunoprecipitation assay buffer containing 1 protease
inhibitor minicomplete cocktail (Roche Applied Science,
Indianapolis, IN) and 5 mmol/L EDTA. Homogenates were
centrifuged at 16,000 g, and the protein concentration in the
supernatant was determined by absorbance using a Nanodrop
spectrophotometer (Thermo Scientiﬁc, Wilmington, DE). A
total of 50 mg was combined with reducing Novex sample
buffer (Invitrogen) and loaded into wells of 4% to 12%
polyacrylamide gel (Invitrogen). Proteins were transferred to
nitrocellulosemembrane and blotted with the polyclonal anti-
ABCC6 antibody K-14 that was raised against the C-terminal
end of the rat ABCC6 for the Western blot detection and
quantiﬁcation of the mouse ABCC6 protein.34,46 Appropriate
secondary antibodies were detected using the Odyssey
infrared imaging system (Li-cor, Lincoln, NE). For densi-
tometry, the net intensity of the target bands was normalized
to that of b-actin (Abcam, Cambridge, MA) to obtain a rela-
tive level of the protein of interest on an unsaturated exposure
using ImageJ software version 1.45k (NIH, Bethesda, MD).162Quantiﬁcation of Hepatic Human ABCC6 Expression
To approximately estimate the level of hepatic expression of
human ABCC6 transfected into Abcc6/ mice and
compared with the endogenous ABCC6 levels in WT con-
trol mice, individual liver lobes were quickly harvested after
euthanasia, placed in OCT compound, and stored at 80C.
The human ABCC6 expression was detected in frozen
sections from Abcc6/ mice transfected with the human
ABCC6 with the anti-human ABCC6 (M6II-31) (Santa
Cruz Biotechnology, Santa Cruz, CA), as described in
Immunohistochemistry and Histological Analysis. Expres-
sion in 10 sections from each of the ﬁve transfected Abcc6/
mice and 10 sections from each of the three WT control mice
was analyzed with ImageJ software version 1.45k using pixel
intensity, and a ratio of expression was calculated with
respect to DAPI nuclear staining. In addition, blind assess-
ment of the amount of individual cells expressing the relevant
membrane-localized ABCC6 was manually counted in the
same sections and expressed as a percentage of the number of
whole DAPI-stained nuclei.
Statistical Analysis
Data were analyzed with the statistical software PRISM
version 5.05a (GraphPad, San Diego, CA). Statistical ana-
lyses were performed using two-tailed unpaired Student’s t-
tests to determine the statistical difference between Abcc6/
groups with HTVI of ABCC6 or empty vector equivalent.
Results were expressed as means  SEM and considered
signiﬁcant for P < 0.05.
Results
Cardiac Dystrophic Mineralization in Abcc6/ Mice
Cryoinjury to the myocardium of Abcc6/ mice resulted in
signiﬁcant and extensive dystrophic calciﬁcation in the re-
gion of injured tissue. The calciﬁcation within the injuredajp.amjpathol.org - The American Journal of Pathology
Figure 2 Histological characterization of myocardium of Abcc6/ mice and mice after cryoinjury or sham treatment. After excision, hearts were ﬁxed in
formalin and parafﬁn embedded. Sections were stained with H&E or Alizarin Red S and imaged. A and B: Images of heart cross sections of Abcc6/mice show the
mineralization occurring after cyroinjury but not in the shameoperated mouse. C and D: The consequence of the ischemic injury after left coronary artery ligation
(H&E staining).Arrows point to the left coronary artery upstream (C) and downstreamof the ligation and the affected portion of themyocardium, which is outlined
(D). E: An image of a serial section from D, stained with Alizarin Red S to reveal the calciﬁcation. Scale barZ 500 mm (A and C).
ABCC6 Modulates Mineralization after MItissue was detectable by eye before excision (Figure 1) and
conﬁrmed histologically (Figure 2). The calciﬁcation was
contained within the site of injury and appeared as a well-
deﬁned necrotic region on the left ventricle wall (Figures 1
and 2). This allowed the precise quantiﬁcation of miner-
alization in the injured section, which was expressed as a
ratio between the injured ventral and uninjured dorsal
sections. Interestingly, the level of calciﬁcation does not
appear to signiﬁcantly abate within 4 weeks (Figure 3A),
indicating the pathological condition is not reversible
within this time frame. Because calciﬁcation quickly fol-
lows induced cardiac necrosis when ABCC6 function is
impaired, we also tested whether Abcc6/ mice responded
to the ligation of the left descending coronary artery as a
method to represent severe cardiac ischemia. This type of
injury resulted in calciﬁcation of the myocardium,
although the injured area was more diffuse and less deﬁned
than with cryoinjury (Figure 2). Calcium deposits were
sporadically located throughout the left ventricle wall from
the region of ligation to the apex of the heart (data not
shown). Because of the diffuse nature of the ischemic
injury, the calciﬁcation phenotype could not be reliablyThe American Journal of Pathology - ajp.amjpathol.orgexpressed as a ratio between the injured and uninjured
regions and was, therefore, evaluated using total tissue
calcium content, as previously described.30 The mortality
resulting from the ligation of the left descending coronary
artery was low (2 of 18 Abcc6/ mice), whereas none of
the nine WT animals died after surgery and within the 4-
week study period.
The ratio between the calcium content in the injured and
uninjured heart sections after cryoinjury was markedly
higher in Abcc6/ mice, at 6.93  1.14 (n Z 22), than
those of the control mice [eg, the shameoperated on, het-
erozygous Abcc6þ/, and WT mice, which had lower ratios
of 1.08  0.30 (n Z 7), 0.92  0.34 (n Z 5), and 1.10 
0.28 (n Z 4), respectively] (Figure 3A). An illustration of
the visible ectopic calciﬁcation on the injury site is shown in
Figure 3B. We did not ﬁnd evidence of mineralization by
histochemical staining of the myocardium of the control
mice (data not shown). For ischemic injury, the total heart
calcium content was also signiﬁcantly elevated in the
experimental mice (n Z 8), with values of 69.6  9.2
mg/dL/mg compared with 36.4  4.6 mg/dL/mg, 22.6  3.6
mg/dL/mg, and 28.4  4.4 mg/dL/g for the Abcc6/Figure 3 Quantiﬁcation of the calciﬁcation
after cardiac injury. A: The calcium content in the
murine hearts after cryoinjury was expressed as a
ratio between the injured ventral/uninjured dorsal
sections. We also compared the cryoinjury calciﬁ-
cation after the transient expression of the WT
ABCC6 and the inactive mutant, V1298F, for various
control mice and at 4 weeks after injury. B and C:
Representative images of the surface lesions
(dashed circles) and calciﬁcation in Abcc6/mice
without and with the expression of the human
ABCC6 cDNA. The calciﬁed deposits (white) were
visibly reduced after the hydrodynamic tail vein
injection of ABCC6 (arrows). D: The level of calci-
ﬁcation after ischemic injury was expressed as the
calcium concentration derived from total heart
because of the diffuse nature of this type of injury.
The results for control mice are also shown. *P <
0.05, **P < 0.01.
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Brampton et alshameoperated on (n Z 6), WT (n Z 7), and WT
shameoperated on (n Z 4) mice, respectively (Figure 3D).
Transient Expression of Human ABCC6 in the Liver
Decreases the Calciﬁcation Phenotype
The efﬁciency of HTVI was ﬁrst tested with a pLIVE vector
carrying the b-galactosidase (LacZ) gene. The results
demonstrated that the transfection resulting from the HTVI
was distributed throughout the liver, with a signiﬁcant pres-
ence in all of the individual hepatic lobes 7 days after injection
(Figure 4, AeC). Furthermore, this transfection was hetero-
geneously distributed within the lobes themselves, with pat-
chy clumps of highly transfected cells adjacent to areas with
relatively low transfection efﬁciency (Figure 4D). We also
veriﬁed that the pLIVE vector resulted in a liver-speciﬁc
expression with no detectable expression in kidneys
(Figure 4, E and F).
Consequently, HTVI into Abcc6/ mice using a human
ABCC6 cDNA vector encoding a functional ABCC6 pro-
tein and targeted for hepatic expression through the pLIVE
liver-speciﬁc promoter resulted in a relatively efﬁcient
expression of the human protein in the mouse liver. To es-
timate the level of functional human ABCC6 protein, a series
of immunoﬂuorescent images (Figure 5A) were generated
with the anti-human ABCC6 and anti-mouse antibodies. The
number of individually transfected hepatocytes withFigure 4 Veriﬁcation of the efﬁciency of HTVI and the overall distri-
bution of the transfected hepatocytes. The commercial pLIVE vector car-
rying liver-speciﬁc promoter, enhancer, and b-galactosidase was used.
After excision, the whole liver and both kidneys were lightly ﬁxed and
prepared for X-gal staining to examine the distribution of expression. AeC:
The method revealed an extensive distribution throughout all lobes of the
liver, although on close examination. D: The distribution of the individual
cells was found to be heterogeneous. E and F: No visible expression was
detected in either kidney, demonstrating the tissue-speciﬁc expression and
the efﬁcient delivery achieved by the HTVI expression of the pLIVE vector.
164immunolabeling associated with the plasma membrane was
estimated at 13% of detectable cell nuclei (Figure 5B),
whereas the morphometric quantiﬁcation of immunoﬂuo-
rescent signals obtained normalized to DAPI staining gave
ratios of approximately 0.9 0.12 and approximately 19.4
1.6, respectively (Figure 5C). The mouse Abcc6 protein
levels in heterozygous Abcc6þ/ animals were quantiﬁed by
densitometry of Western blot images (1869  941versus
4944 1159) and were found to be 38% of the WT amounts
(Figure 5, D and E). These immunoﬂuorescent images and
Western blot analysis with the K-14 antibody highlighted the
sparse, but signiﬁcant, expression of the human ABCC6 in
mouse livers in patterns similar to the b-galactosidasee
transfected mice (Figure 4). Indeed, we detected the ABCC6
protein in groups of heterogeneously distributed cells
throughout the liver, comparable to the results of a previous
study.34 As expected, no human or mouse Abcc6 mRNA
(data not shown) or protein (Figure 5F) was detected in
noninjected control Abcc6/ animals.
Despite the expression level of the human protein being
low, as estimated by the number of positively transfected
hepatocytes, the amount of ABCC6 protein produced was
sufﬁcient to signiﬁcantly reduce the calciﬁcation of cryoin-
jured cardiac tissue in Abcc6/ mice (Figure 3, A and C).
The human ABCC6-transfected mice had a calcium ratio of
2.55 0.57 (nZ 10), which represented a 2.7-fold reduction
in mineralization when compared with an Abcc6-null mouse
at 6.93  1.14 (Figure 3A). There was no statistically sig-
niﬁcant difference between the levels of calciﬁcation after
cryoinjury in the human ABCC6-transfected mice and the
sham control animals. To ﬁrmly attribute the reduction of
calciﬁcation to ABCC6 function, we repeated the cryoinjury
procedure with Abcc6/ mice subjected to HTVI with a
plasmid carrying the human ABCC6 cDNA with the PXE-
causing p.V1298F mutation.7 We have previously found
this mutant to be transport inactive but fully integrated to the
plasma membrane.34 As expected, the high calciﬁcation ratio
was similar to the non-treated Abcc6/ mice (Figure 3A),
indicating that the calciﬁcation rescue was, in fact, due to a
functional human ABCC6.
ABCC6 Deﬁciency Leads to Changes in the Levels of
Several Mineralization Regulators
We detected an increased expression or a change in the
distribution pattern of OPN and ucMGP in the cryoinjury
and ischemic injury areas of Abcc6/ mice. OC showed no
signiﬁcant difference with ELISA measurements or immu-
noﬂuorescence (Figures 6 and 7). In cryoinjured Abcc6/
mice, we found a large increase in OPN levels (Figure 6),
which were distributed throughout the area of necrotic tis-
sue. There was a large increase in the detectable amount of
OPN in the experimental animals when compared with
that in control tissues (Figure 7). More interestingly, we
found signiﬁcantly increased amounts of ucMGP tightly
localized in the areas of mineralization. Serial sections onajp.amjpathol.org - The American Journal of Pathology
Figure 5 Evaluation of ABCC6protein levels after
HTVI. The level of expressionof humanABCC6 inHTVI-
treated Abcc6/ mice was estimated and compared
with WT levels using immunoﬂuorescent images (A)
and ImageJ software version 1.45k, by manually
counting the number of cells with membrane
expression of the protein and comparing with the
number of DAPI-stained nuclei (B) and by morpho-
metric analysis of pixel intensity (nZ 5 HTVI-treated
mice and nZ 3 for WTmice with 10 random nonserial
sections counted from each liver) (C). The mouse
ABCC6 protein was detected on frozen sections by
immunoﬂuorescence with the S-20 polyclonal anti-
body (green). Human ABCC6 was revealed with the
M6II-31monoclonal antibody (red) showing sporadic
staining, as expected. Liver tissue from an Abcc6/
mouse was used as a negative control for the S-20
antibody. D: Representative Western blot images that
include the clear detection of the human and mouse
ABCC6 in the liver of Abcc6/mice are shown. E: The
level of mouse ABCC6 expression in heterozygous
mice was quantiﬁed by using Western blot analysis
with the K-14 antibody. The detection of b-actin was
used as a normalizing control. F: Representative
Western blot images showing the absence of detec-
tion of the mouse ABCC6 in liver extracts of two
Abcc6/mice with the K-14 antibody. The detection
of b-actin was used as a loading control. Scale bars:
100 mm (A). *P < 0.05, **P < 0.01.
ABCC6 Modulates Mineralization after MIexperimental mice and control animals are noted in
Figure 7. A similar pattern was observed in the ischemic
heart areas. However, because of the more diffuse nature of
the damage in this model, colocalizing the immunostainings
with the areas of calcium deposits was less evident
(Figure 7). The control Abcc6þ/ heterozygous mice
exhibited little OC or ucMGP expression in the injured
cardiac tissue, but we still detected small amounts of OPNFigure 6 ELISA quantiﬁcation of calciﬁcation regulators in the myocardium of
and total proteins were extracted. The levels of OC, OPN, and MGP were quantiﬁed
tissues. *P < 0.05, ***P < 0.001. Cryo, cryoinjured.
The American Journal of Pathology - ajp.amjpathol.orgdistributed throughout the injured area, despite the notice-
able absence of mineralization in cardiac tissues (Figure 7).
Transient Expression of Human ABCC6 Normalizes the
Expression Pattern of MGP
Along with reduced calciﬁcation, the cryoinjured area of
cardiac tissue of Abcc6/ mice expressing the humanAbcc6/ mice after cardiac injury. The injured cardiac regions were excised
with commercially available kits. The results are shown as pg/mL per mg of
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Figure 7 Immunoﬂuorescent detection of calci-
ﬁcation regulators in the myocardium of Abcc6/
mice after ischemic injury and cryoinjury. Immuno-
ﬂuorescent detection of calciﬁcation regulators in
experimental animals. Frozen serial sections from
the heart of Abcc6/ mice and Abcc6/ mice
expressing the human ABCC6 protein were used for
both immunoﬂuorescent and Alizarin Red S staining.
We observed large positive staining of OC, OPN, and
ucMGP (green) in the injured regions, which sug-
gested a role for these regulators in the minerali-
zation response to the cryoinjuries and ischemic
injuries. Immunoﬂuorescent detection of calciﬁca-
tion regulators is shown for control animals. Frozen
serial sections from the heart of heterozygous
Abcc6þ/ and WT mice were used. Little or no evi-
dence of calciﬁcation (Alizarin Red S) or change in
the immunoﬂuorescent staining patterns was
observed in these control tissues. Negative controls
were performed by omitting the primary anti-mouse
ucMGP antibody. Nuclei were stained with DAPI. The
circles indicate the position of the ligating sutures
placed to induce permanent cardiac ischemia. Scale
bar Z 100 mm.
Brampton et alABCC6 showed limited changes in OC and OPN staining
when compared with Abcc6/ animals (Figure 7). No
changes could be observed between treated and untreated
mice using the OC ELISA quantiﬁcation (Figure 6). The
ELISA quantiﬁcation of OPN showed a small (15%), yet
signiﬁcant, reduction in protein level in the cryoinjured re-
gion (Figure 6). As for ucMGP, we found that there was still
some positive staining associated with those areas of cal-
cium deposition identiﬁed with Alizarin Red S staining
(Figure 7); however, the overall levels in the injured site
were almost completely normalized (Figure 6).Mineralization Is Not Due to an Alteration in Cell Death
At 1, 3, and 7 days after cryoinjury, the Abcc6/ and WT
hearts showed similar levels and patterns of apoptosis
(Figure 8). At 24 hours after cryoinjury, apoptosis was
extensive in and around the injured areas, with a concen-
tration at the surface of the heart lessening in intensity
farther into the tissue. After 3 days, the level of apoptosis
detected by the TUNEL method was considerably reduced
and showed a similar sporadic pattern in both Abcc6/ and
WT mice. By day 7 after cryoinjury, little apoptosis was
seen in either mouse strain. TUNEL staining did not spe-
ciﬁcally colocalize with areas of calcium deposition in the166Abcc6/ mice and, in fact, appeared to involve a larger
region, which further indicates the lack of contribution of
cell death to the mineralization phenotype (Figure 8).
Discussion
The DCC phenotype (in mice) is one of the four similar
pathological calciﬁcation phenotypes linking ABCC6 deﬁ-
ciency to diseases such as PXE, GACI, and b-thalas-
semia.6,8,10,13,22,25 In this study, we investigated the effect of
variable ABCC6 expression in the calciﬁcation response to
cardiac injury using two models of cardiac injuries, non-
ischemic cryoinjury and the pathologically relevant coro-
nary ligation. Furthermore, we examined the recruitment of
calciﬁcation-related proteins (OC, OPN, and MGP) in car-
diac tissues after cryoinjury and ischemic injury.
The mouse Abcc6 gene encodes an ABC-transporter pro-
tein primarily expressed in the liver and, to a lesser extent, in
the kidney.47 We used Western blot analysis and immuno-
ﬂuorescence imaging to estimate the expression of the
ABCC6 protein in the liver of WT and Abcc6/ mice. We
found the expression in the heterozygous Abcc6þ/ mice to
be at approximately 38% of theWT levels. Because this level
of expression was sufﬁcient to prevent the DCC phenotype,
we tested whether a gene therapy approach could improveajp.amjpathol.org - The American Journal of Pathology
Figure 8 Mineralization is not due to altered
cell death. At 1, 3, and 7 days after cryoinjury,
Abcc6/ and WT hearts were harvested and
stained with Alizarin Red S to reveal the progres-
sion of cardiac calciﬁcation (arrows). The level of
apoptosis detected by TUNEL showed similar levels
and patterns of apoptosis (green ﬂuorescence)
throughout the injured sections of the Abcc6/
and WT tissues. Nuclei were stained with DAPI. The
images were centered on the injured areas, which
varied slightly for each mouse. Scale bars: 100 mm.
ABCC6 Modulates Mineralization after MIthis acute calciﬁcation phenotype. We applied HTVI to ex-
press a functional human ABCC6 cDNA under the control of
a liver-speciﬁc promoter in Abcc6/ mice or to deliver
control vectors, either empty or carrying an inactivated
ABCC6 mutant. The number of hepatocytes showing a
detectable expression of human ABCC6 (approximately 13%
of total) was counted and found signiﬁcant 7 days after HTVI.
Although the estimated protein levels were markedly lower,
with an immunoﬂuorescent signal/DAPI ratio of approxi-
mately 0.9 when compared with the WT ratio of approxi-
mately 19.4, this relatively modest level of human ABCC6
expression is probably an underestimation of the initial
amount because HTVI expression peaks within 24 hours
before slowly decreasing.26,42,43 However, this small amount
of ABCC6 expression in liver was sufﬁcient to signiﬁcantly
(60%) decrease the DCC phenotype to a level comparable
to controls. Therefore, we estimated that the minimum level
of ABCC6 protein necessary to achieve complete inhibition
of mineralization in a C57BL/6J background lies well below
38%, which is found in heterozygous mice. Our ﬁndings
demonstrate that the method of transient delivery of the
human ABCC6 results in a physiologically functional protein
that requires few hepatocytes expressing ABCC6 (in mice) to
positively affect the DCC response. Furthermore, in agree-
ment with our previous results,13 we suggest that the liver
should be the target organ for possible future gene therapy
intervention in diseases characterized by reduced ABCC6
activity.The American Journal of Pathology - ajp.amjpathol.orgWe have established that both superﬁcial necrosis-
inducing cryolesions and ischemic events can trigger DCC
in mice lacking ABCC6. After cryoinjury, calciﬁcation oc-
curs quickly between days 3 and 7.35 The ischemia method
on the other hand, requires 4 weeks for a reasonable calci-
fying response. Because HTVI results in the expression of a
recombinant protein for a maximum of 1 to 2 weeks,26,42 we
have not assessed the possibility of transient gene therapy to
rescue cardiac mineralization under ischemic conditions.
Repeated tail vein injection could be an option to overcome
this obstacle; however, the risk of HTVI to an already
compromised heart in these mice is signiﬁcant.
A recent study by Mungrue et al48 demonstrated the rela-
tionship between ABCC6 function and infarct size under
short-term ischemia-reperfusion conditions (<1hour). In their
studies, the authors noted the absence of calciﬁcation in the
myocardium of both of the Abcc6-deﬁcient mice tested after
30 minutes of ischemia, followed by 48 hours of reperfusion.
This suggests that only a sustained cardiac injury will lead to
signiﬁcant calciﬁcation in the absence ofABCC6. The authors
also hypothesized a link betweenABCC6 and the inhibition of
the anti-apoptotic bone morphogenetic protein 4/9 signaling
pathway. It would be valuable to investigate this mechanism
further with respect to apoptosis and mineralization.
Dystrophic calciﬁcation shares similarities with bone
mineralization. In this study, we also focused on how the
level of ABCC6 affected relevant mineralization-related
proteins that might be downstream effectors. We observed167
Brampton et alvariation in the level or distribution of OPN and MGP,
notably in its undercarboxylated form (ucMGP) in the injured
cardiac tissue of Abcc6/ mice in both the cryoinjured and
ischemic groups, but not for OC. Of particular interest was the
fact that OPN and ucMGP were not affected equally by both
the injuries and the partial restoration of the ABCC6 function
in liver. Interestingly, we found that MGP, an inhibitor of
calciﬁcation, was tightly colocalized with the calciﬁcation
nodules in the injured myocardium, and its elevated levels
were essentially normalized in HTVI-rescued and in hetero-
zygous Abcc6þ/ mice. Therefore, one may suggest that the
tissue surrounding the sites of calciﬁcation reacts to contain
the developing mineralization by producing this inhibitor of
calciﬁcation, albeit in an inactive undercarboxylated form.
(uc)MGP was shown to be associated with the chronic
extracellular calciﬁcation in patients with PXE.36,37 Our re-
sults show that ucMGP also plays a role in the intracellular
calciﬁcation of the acute DCC phenotype. However, it is still
unclear if the MGP response is related to the calciﬁcation, the
ABCC6 status, or both. One would need to look for inter-
mediary elements controlling MGP expression, such as
related bone morphogenetic protein levels.48
OC is a key regulator of calciﬁcation and is differentially
expressed in areas of calciﬁed lesions in vascular tis-
sues.40,41,49 Herein, we only observed a modest redistribu-
tion, and nonsigniﬁcant changes, of OC levels in the injured
myocardium of Abcc6/ mice, indicating a limited role, if
any, for OC in the DCC phenotype. OPN also plays a critical
role in vascular mineralization and inﬂammation,50 but
more interestingly, it is up-regulated in cardiac tissues in
DCC-susceptible B6.C3HDyscalc1 mice but not in the DCC-
resistant C57BL/6J mice.23,28,38 Both B6.C3HDyscalc1
animals and the C57BL/6J mice share the same genetic
background and only differ on the Dyscalc1 locus on chro-
mosome 7 that contains the mutated Abcc6 gene. Conse-
quently, it was no surprise that OPN level and distribution
were dramatically affected in both cryoinjured and ischemic
cardiac tissues in Abcc6/mice. However, the novelty of our
result is that the modulation of ABCC6 expression in the liver
positively affected OPN levels in heart injury. Taken together
with the fact that one of the authors (Z.A.) has recently
identiﬁed one of the transcription factors responsible for the
Abcc6-dependent OPN transactivation in B6.C3HDyscalc1
mice,38 it appears that ABCC6 function directly inﬂuences
OPN expression. Furthermore, Hendig et al51 have reported
an association of polymorphisms within the promoter region
of OPN and calciﬁcation in patients with PXE.
Our study has clearly developed further the notion that
ABCC6 function is not limited to the extracellular calciﬁ-
cation of elastic ﬁber in rare diseases (PXE and GACI) but is
more likely to have wider ramiﬁcations toward a variety of
cellular and molecular processes. Both PXE and DCC are
autosomal recessive traits, and the expression of a small
amount or a single allele of ABCC6 is sufﬁcient to dramat-
ically decrease the susceptibility to calciﬁcation.20,21 We
have not observed obvious signs of mineralization after168cardiac cryoinjury in heterozygous animals. However, the
mice used in these studies are inbred strains with genetic
characteristics not fully superimposable to that of humans
because it seems that, in older human subjects with reduced
ABCC6 function, some show mild PXE manifestations
(A.A.B.B., unpublished data).13,52 Other studies have also
suggested that human heterozygous carriers of ABCC6 mu-
tations are more likely to develop complications resulting
from cardiovascular incidents,53,54 although this is not
without some controversy.55 Because the estimated fre-
quency of heterozygous carriers of ABCC6 mutations in the
general population is about 1 in 80,56 a signiﬁcant portion of
the general population is likely at an increased risk of car-
diovascular calciﬁcation, especially if modifying loci are
present. In mice, the ABCC6 anti-mineralization potential is
modulated by three other loci of unknown characteristics on
mouse chromosomes 4, 12, and 14,29 and probably more.57,58
Similar loci could exist in humans as well.
In summary, we have shown that both cryoinjury and
ischemic injury lead to acute calciﬁcation within the
myocardium of Abcc6/ mice. This phenotype and the
levels of local inhibitors of calciﬁcation were modulated by
the successful expression of a functional human ABCC6
protein in the liver of Abcc6/mice. Our results showed that
ABCC6 is, therefore, a critical determinant of acute calciﬁ-
cation in nonelastic tissues, in addition to being a modulator
of chronic mineralization of connective tissues, as previously
described.6,8,9,20,21
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